Albireo: Failed deal, bidding war paved the way for Ipsen's $952M rare disease buyout

Ipsen may have a mysterious company to thank for its $952 million takeover of Albireo Pharma. While the French pharma ultimately elbowed two potential buyers to win over Albireo, negotiating down to the final rounds, it was an unnamed "Company A" that kicked off the M&A action, a new SEC...